StockMacro
Menu

SAB Biotherapeutics

$2.81 -26% in 6 monthsMarket cap $253.1M

SABS on XNAS, Health Care, SAB Biotherapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

Institutional holders rose 18% to 100 while losses reached $80.5M over 12 months.

  • BadShort interest rose 4.7% over two weeks, now 5.6% of shares

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
86
Website
sab.bio
Listed
Nasdaq, US
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $22.3M.
Quarter to 31 Dec 2021: revenue $11.1M, net income -$17.6MQuarter to 31 Dec 2021: revenue $11.1M, net income -$17.6MQuarter to 31 Mar 2022: revenue $11.8M, net income $986KQuarter to 31 Mar 2022: revenue $11.8M, net income $986KQuarter to 30 Jun 2022: revenue $6.4M, net income -$4.8MQuarter to 30 Jun 2022: revenue $6.4M, net income -$4.8MQuarter to 30 Sep 2022: revenue $3.6M, net income -$7.1MQuarter to 30 Sep 2022: revenue $3.6M, net income -$7.1MQuarter to 31 Dec 2022: revenue $2.2M, net income -$7.9MQuarter to 31 Dec 2022: revenue $2.2M, net income -$7.9MQuarter to 31 Mar 2023: revenue $581K, net income -$7.4MQuarter to 31 Mar 2023: revenue $581K, net income -$7.4MQuarter to 30 Jun 2023: revenue $86K, net income -$6.9MQuarter to 30 Jun 2023: revenue $86K, net income -$6.9MQuarter to 30 Sep 2023: revenue $1.3M, net income -$5.1MQuarter to 30 Sep 2023: revenue $1.3M, net income -$5.1MQuarter to 31 Dec 2023: revenue $305K, net income -$22.9MQuarter to 31 Dec 2023: revenue $305K, net income -$22.9MQuarter to 31 Mar 2024: revenue $945K, net income -$5.0MQuarter to 31 Mar 2024: revenue $945K, net income -$5.0MQuarter to 30 Jun 2024: revenue $263K, net income -$7.3MQuarter to 30 Jun 2024: revenue $263K, net income -$7.3MQuarter to 30 Sep 2024: revenue –, net income -$10.3MQuarter to 31 Dec 2024: revenue $115K, net income -$11.4MQuarter to 31 Dec 2024: revenue $115K, net income -$11.4MQuarter to 31 Mar 2025: revenue –, net income -$5.2MQuarter to 30 Jun 2025: revenue –, net income -$10.1MQuarter to 30 Sep 2025: revenue –, net income $45.4MQuarter to 31 Dec 2025: revenue –, net income -$16.9MQuarter to 31 Mar 2026: revenue –, net income -$18.9MQuarter to 30 Jun 2026: revenue –, net income -$22.5MQuarter to 30 Sep 2026: revenue –, net income -$22.3M
31 Dec 2021RevenueNet incomeNet losstallest bar $45.4M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–-$22.3M
30 Jun 2026–-$22.5M
31 Mar 2026–-$18.9M
31 Dec 2025–-$16.9M
30 Sep 2025–$45.4M
30 Jun 2025–-$10.1M
31 Mar 2025–-$5.2M
31 Dec 2024$115K-$11.4M
30 Sep 2024–-$10.3M
30 Jun 2024$263K-$7.3M
31 Mar 2024$945K-$5.0M
31 Dec 2023$305K-$22.9M
30 Sep 2023$1.3M-$5.1M
30 Jun 2023$86K-$6.9M
31 Mar 2023$581K-$7.4M
31 Dec 2022$2.2M-$7.9M
30 Sep 2022$3.6M-$7.1M
30 Jun 2022$6.4M-$4.8M
31 Mar 2022$11.8M$986K
31 Dec 2021$11.1M-$17.6M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$80.5M $18.7M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -42.8% -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $104.0M $110.9M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $2.34
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 1.2 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
SAB BiotherapeuticsSABS (this company) $253.1Mloss–––
Editas MedicineEDIT $253.1Mloss5.1+7.4%-145%
Eikon TherapeuticsEIKN $256.8M––––
OcugenOCGN $260.6Mloss54.5-11%–
Lexeo TherapeuticsLXEO $245.1Mloss–––
Protalix BioTherapeuticsPLX $244.5M11.92.9+37%24.3%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+18%

100 13F filers vs 85

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

87%

78.3M shares held by 13F filers (30 Sep 2026) of 90.1M outstanding (2 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

5.6%

5.0M shares sold short (30 Oct 2026) of 90.1M outstanding (2 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

8.3

5.0M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+4.7%

4.8M shares sold short in the report before, 5.0M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

49%

49% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 49%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

8

8 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

8.0×

8 articles in the last 7 days; its usual week has 1.

Price $2.81 on 20 Nov 2026, -26% over 12 months (12-month range $2.49 to $4.59)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders bought a net $0 in the last 12 months (the 12 months before: $0).
Revenue per quarter. Revenue $115K in the latest quarter, -62% on a year earlier.
Capital spending per quarter. Capital spending $1.3M in the latest quarter.
Institutional holders (13F filers). 100 13F filers reported holding it in the latest 13F quarter, +194% on a year earlier.
Lobbying spend. Lobbying spend: $0 published in the last 12 months.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
19 May 2026Sharp changeMany funds opening a new position: many funds opening a new position, 29 vs usual 4 (2026-03-31); 7.2x the same period a year earlier
17 Feb 2026Sharp changeShort interest spike: short interest spike, 1.9M vs usual 265K (2026-01-30); 16.4x the same period a year earlier
17 Feb 2026Sharp changeMany funds opening a new position: many funds opening a new position, 20 vs usual 4 (2025-12-31); 5.0x the same period a year earlier
3 Feb 2026Sharp changeShort interest spike: short interest spike, 1.6M vs usual 122K (2026-01-15); 29.2x the same period a year earlier
13 Jan 2026Sharp changeShort interest spike: short interest spike, 1.4M vs usual 117K (2025-12-31); 39.7x the same period a year earlier
7 Jan 20268-K and other filingsDirector or officer change
7 Jan 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
30 Dec 2025Sharp changeShort interest spike: short interest spike, 901K vs usual 107K (2025-12-15); 16.0x the same period a year earlier
16 Dec 2025Sharp changeShort interest spike: short interest spike, 702K vs usual 99K (2025-11-28); 7.1x the same period a year earlier
2 Dec 2025Sharp changeShort interest spike: short interest spike, 677K vs usual 96K (2025-11-14); 16.9x the same period a year earlier
18 Nov 2025Sharp changeShort interest spike: short interest spike, 697K vs usual 82K (2025-10-31); 11.9x the same period a year earlier
28 Oct 2025Sharp changeShort interest spike: short interest spike, 693K vs usual 76K (2025-10-15); 8.7x the same period a year earlier
30 Sep 20258-K and other filingsDirector or officer change
26 Sep 20258-K and other filingsDirector or officer change
26 Sep 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
2 Sep 2025Sharp changeShort interest spike: short interest spike, 502K vs usual 58K (2025-08-15); 19.1x the same period a year earlier
12 Aug 2025Sharp changeShort interest spike: short interest spike, 746K vs usual 55K (2025-07-31); 26.1x the same period a year earlier
5 Aug 20258-K and other filingsPrivate placement of securities (Form D)
5 Feb 20258-K and other filingsCompleted an acquisition or asset sale
31 Jul 20248-K and other filingsDirector or officer change
30 May 20248-K and other filingsDirector or officer change
15 May 20248-K and other filingsReport will be filed late
7 May 20248-K and other filingsDirector or officer change
8 Mar 20248-K and other filingsDirector or officer change
2 Feb 20248-K and other filingsDirector or officer change
20 Nov 20238-K and other filingsDirector or officer change
27 Oct 20238-K and other filingsDirector or officer change
16 Oct 20238-K and other filingsPrivate placement of securities (Form D)
2 Oct 20238-K and other filingsDirector or officer change
2 Oct 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
21 Aug 20238-K and other filingsChanged its auditor
14 Aug 20238-K and other filingsReport will be filed late
31 Jul 20238-K and other filingsChanged its auditor
30 May 2023Sharp changeShort interest spike: short interest spike, 665K vs usual 231K (2023-05-15); 2.6x the same period a year earlier
16 May 2023Sharp changeShort interest spike: short interest spike, 519K vs usual 231K (2023-04-28); 2.0x the same period a year earlier
4 Apr 20238-K and other filingsDirector or officer change
4 Apr 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
31 Mar 20238-K and other filingsReport will be filed late
31 Mar 20238-K and other filingsEarlier financial statements can no longer be relied on
27 Jan 20238-K and other filingsDelisting notice or listing transfer
20 Jan 2023Lobbying filinglobbying engagement terminated (DLA PIPER LLP (US))
7 Oct 20228-K and other filingsDelisting notice or listing transfer
22 Aug 20228-K and other filingsRegistered new securities for sale (S-1)
25 Feb 2022Sharp changeLobbying on a new issue: lobbying on a new issue: PHA (2021-12-31)
17 Feb 2022Lobbying filingnew lobbying registration (DLA PIPER LLP (US))
6 Jan 20228-K and other filingsDirector or officer change
3 Dec 20218-K and other filingsRegistered new securities for sale (S-1)
Insider net buying (open market)
Month from 1 Sep 2022: $18K published
Month from 1 Dec 2023: $16K published
Revenue per quarter
Quarter ended 31 Mar 2021: $16.9M; public on 13 May 2022
Quarter ended 30 Jun 2021: $18.2M; public on 11 Aug 2022
Quarter ended 30 Sep 2021: $14.7M; public on 15 Nov 2022
Quarter ended 31 Dec 2021: $11.1M; public on 30 Mar 2022
Quarter ended 31 Mar 2022: $11.8M, -30% on a year earlier; public on 13 May 2022
Quarter ended 30 Jun 2022: $6.4M, -65% on a year earlier; public on 11 Aug 2022
Quarter ended 30 Sep 2022: $3.6M, -76% on a year earlier; public on 15 Nov 2022
Quarter ended 31 Dec 2022: $2.2M, -80% on a year earlier; public on 15 Apr 2023
Quarter ended 31 Mar 2023: $581K, -95% on a year earlier; public on 16 May 2023
Quarter ended 30 Jun 2023: $86K, -99% on a year earlier; public on 22 Aug 2023
Quarter ended 30 Sep 2023: $1.3M, -65% on a year earlier; public on 14 Nov 2023
Quarter ended 31 Dec 2023: $305K, -86% on a year earlier; public on 30 Mar 2024
Quarter ended 31 Mar 2024: $945K, +63% on a year earlier; public on 21 May 2024
Quarter ended 30 Jun 2024: $263K, +208% on a year earlier; public on 9 Aug 2024
Quarter ended 31 Dec 2024: $115K, -62% on a year earlier; public on 1 Apr 2025
Capital spending per quarter
Quarter ended 31 Mar 2021: $1.9M; public on 13 May 2022
Quarter ended 30 Jun 2021: $3.5M; public on 11 Aug 2022
Quarter ended 30 Sep 2021: $3.2M; public on 15 Nov 2022
Quarter ended 31 Dec 2021: $2.4M; public on 30 Mar 2022
Quarter ended 31 Mar 2022: $1.4M, -28% on a year earlier; public on 13 May 2022
Quarter ended 30 Jun 2022: $613K, -82% on a year earlier; public on 11 Aug 2022
Quarter ended 30 Sep 2022: $79K, -98% on a year earlier; public on 15 Nov 2022
Quarter ended 31 Dec 2022: $118K, -95% on a year earlier; public on 15 Apr 2023
Quarter ended 31 Mar 2023: $21K, -98% on a year earlier; public on 16 May 2023
Quarter ended 30 Jun 2023: $23K, -96% on a year earlier; public on 22 Aug 2023
Quarter ended 30 Sep 2023: $85K, +8.7% on a year earlier; public on 14 Nov 2023
Quarter ended 31 Dec 2023: $68K, -42% on a year earlier; public on 30 Mar 2024
Quarter ended 31 Mar 2024: $129K, +506% on a year earlier; public on 21 May 2024
Quarter ended 30 Jun 2024: $53K, +131% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $100K, +18% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $55K, -18% on a year earlier; public on 1 Apr 2025
Quarter ended 31 Mar 2026: $983K; public on 13 May 2026
Quarter ended 30 Jun 2026: $1.6M; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $1.3M; public on 6 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 32; public on 14 Feb 2022
31 Mar 2022 report: 27; public on 16 May 2022
30 Jun 2022 report: 37; public on 15 Aug 2022
30 Sep 2022 report: 37; public on 14 Nov 2022
31 Dec 2022 report: 36; public on 14 Feb 2023
31 Mar 2023 report: 38; public on 15 May 2023
30 Jun 2023 report: 35; public on 14 Aug 2023
30 Sep 2023 report: 32; public on 14 Nov 2023
31 Dec 2023 report: 42; public on 14 Feb 2024
31 Mar 2024 report: 23; public on 15 May 2024
30 Jun 2024 report: 22; public on 14 Aug 2024
30 Sep 2024 report: 23; public on 14 Nov 2024
31 Dec 2024 report: 25; public on 14 Feb 2025
31 Mar 2025 report: 26; public on 15 May 2025
30 Jun 2025 report: 22; public on 14 Aug 2025
30 Sep 2025 report: 34; public on 14 Nov 2025
31 Dec 2025 report: 48; public on 17 Feb 2026
31 Mar 2026 report: 75; public on 15 May 2026
30 Jun 2026 report: 85; public on 14 Aug 2026
30 Sep 2026 report: 100; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $20K published
Quarter from 1 Apr 2022: $40K published
Quarter from 1 Jul 2022: $60K published
Quarter from 1 Oct 2022: $30K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is 13F holders (funds reporting the stock) at 100 (30 Sep 2026), 3.4× its normal reading; higher than 100% of its own history.
  • Insider net buying (open market): Insiders bought a net $0 in the last 12 months (the 12 months before: $0).
  • Revenue per quarter: Revenue $115K in the latest quarter, -62% on a year earlier.
  • Capital spending per quarter: Capital spending $1.3M in the latest quarter.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 13 insider trades

No trades in the last 90 days; the latest was filed 8 Dec 2023. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
8 Dec 2023Eddie Joe SullivanChief Executive OfficerBuy1,740$0.88$2KForm 4
30 Nov 2023Michael KingCHIEF FINANCIAL OFFICERBuy5,000$0.90$4KForm 4
30 Nov 2023Samuel J ReichExecutive ChairmanBuy11,000$0.89$10KForm 4
14 Sep 2022Christine E HamiltonDirector, 10% ownerBuy10,000$0.73$7KForm 4
8 Sep 2022Eddie Joe SullivanCHIEF EXECUTIVE OFFICERBuy14,000$0.74$10KForm 4
16 Nov 2021Russell P BeyerChief Financial OfficerSell278$7.90$2KForm 4
15 Oct 2021Ilan KatzDirector, 10% ownerBuy500$10.11$5KForm 4
15 Oct 2021Samuel J ReichCEO and CFOBuy1,000$10.11$10KForm 4

100 institutions reported shares at the end of Q3 2026, 87% of the shares outstanding; 18 opened a position, 6 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Caligan Partners LP8.7M9.70%$27.7M+770K+9.7%
Vivo Capital, LLC6.9M7.68%$21.9M-385K-5.3%
Perceptive Advisors LLC6.6M7.36%$21.0MNo change
Adage Capital Partners GP, L.L.C.6.4M7.11%$20.3MNo change
Ra Capital Management, L.P.4.4M4.89%$14.0MNo change
Balyasny Asset Management L.P.3.8M4.17%$11.9MNo change
BlackRock, Inc.3.6M3.97%$11.3M+506K+17%
Millennium Management LLC3.5M3.83%$10.9M+705K+26%
Vanguard Capital Management LLC3.1M3.43%$9.8M+116K+3.9%
Commodore Capital LP2.9M3.19%$9.1MNo change

Company events

All 55 company events

In 12 months: 2 major agreements, 1 director or officer change. Results releases and routine reports are left out.

FiledWhat happenedSource
4 May 2026Signed a major agreement8-K
18 Mar 2026Signed a major agreement8-K
7 Jan 2026Director or officer change8-K
30 Sep 2025Director or officer change8-K
26 Sep 2025Director or officer changeSame filing: shareholder vote results8-K
5 Aug 2025Private placement of securities (Form D)$175.0M sold of $175.0M offeredD
21 Jul 2025Signed a major agreementSame filing: sold shares privately, changed its bylaws or fiscal year8-K
5 Feb 2025Signed a major agreement; Completed an acquisition or asset sale8-K

Reported lobbying spend: $30K in Q3 2022, $60K in Q2 2022. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
31 Dec 2022EndedDla Piper LLP (US)for Sab Biotherapeutics, Inc.Federal contracts for biopharmaceuticals development.PharmacyFiling
1 Jan 2022EndedArentfox Schiff LLPfor Sab Biotherapeutics, Inc.Not statedFiling
29 Nov 2021NewDla Piper LLP (US)for Sab Biotherapeutics, Inc.Provisions relating to the manufacturing priorities for biopharmaceuticals.PharmacyFiling
6 Oct 2020NewArentfox Schiff LLPfor Sab Biotherapeutics, Inc.Medical therapeutic development and fundingMEDFiling
31 Dec 2015EndedChamber Hill Strategiesfor Sab Biotherapeutics, Inc.Not statedFiling
3 Nov 2014NewChamber Hill Strategiesfor Sab Biotherapeutics, Inc.Education awareness and funding related to infectious diseases, including ebola.Health issues, BudgetFiling
Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

17 Feb 2026confirmed

Confirmed across sources Institutional holdings and Short interest and volume

SAB Biotherapeutics (SABS): had 1.6M shares sold short in the 15 Jan 2026 report, 29× the same report last year, while it saw 20 13F filers open a new position in the quarter ended 31 Dec 2025, 5.0× the same quarter last year. Two unrelated kinds of activity within 14 days.

  • Short interest and volume: Short interest spike, became public on 28 Jan 2026
  • Institutional holdings: Many funds opening a new position, became public on 17 Feb 2026
  • Short interest and volume: Short interest spike, became public on 11 Feb 2026
2025-01-15: 53K2025-01-31: 118K2025-02-14: 68K2025-02-28: 125K2025-03-14: 115K2025-03-31: 93K2025-04-15: 72K2025-04-30: 100K2025-05-15: 72K2025-05-30: 37K2025-06-13: 34K2025-06-30: 21K2025-07-15: 21K2025-07-31: 746K2025-08-15: 502K2025-08-29: 440K2025-09-15: 405K2025-09-30: 498K2025-10-15: 693K2025-10-31: 697K2025-11-14: 677K2025-11-28: 702K2025-12-15: 901K2025-12-31: 1.4M2026-01-15: 1.6M
The 15 Jan 2026 report against the 24 reports before it. this reportearliernormal: 122K
See the evidence (3 changes)

Short interest and volume: Short interest spike became public on 28 Jan 2026

SAB Biotherapeutics had 1.6M shares sold short in the 15 Jan 2026 report, 29× the same report last year.

This period
1.6M (the 15 Jan 2026 report)
Normal report (median of 24 earlier)
122K
Typical spread (median absolute deviation)
101K
How far from its usual level
+9.7
Same report last year
53K
History used
1,539 days
2025-01-15: 53K2025-01-31: 118K2025-02-14: 68K2025-02-28: 125K2025-03-14: 115K2025-03-31: 93K2025-04-15: 72K2025-04-30: 100K2025-05-15: 72K2025-05-30: 37K2025-06-13: 34K2025-06-30: 21K2025-07-15: 21K2025-07-31: 746K2025-08-15: 502K2025-08-29: 440K2025-09-15: 405K2025-09-30: 498K2025-10-15: 693K2025-10-31: 697K2025-11-14: 677K2025-11-28: 702K2025-12-15: 901K2025-12-31: 1.4M2026-01-15: 1.6M
the 15 Jan 2026 report24 earlier reportsnormal: 122K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 17 Feb 2026

SAB Biotherapeutics saw 20 13F filers open a new position in the quarter ended 31 Dec 2025, 5.0× the same quarter last year.

This period
20 (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
4
Typical spread (median absolute deviation)
1.5
How far from its usual level
+5.3
Same quarter last year
4
History used
1,553 days
2023-12-31: 102024-03-31: 22024-06-30: 22024-09-30: 42024-12-31: 42025-03-31: 42025-06-30: 32025-09-30: 132025-12-31: 20
the quarter ended 31 Dec 20258 earlier quartersnormal: 4

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Short interest and volume: Short interest spike became public on 11 Feb 2026

SAB Biotherapeutics had 1.9M shares sold short in the 30 Jan 2026 report, 16× the same report last year.

This period
1.9M (the 30 Jan 2026 report)
Normal report (median of 24 earlier)
265K
Typical spread (median absolute deviation)
232K
How far from its usual level
+4.9
Same report last year
118K
History used
1,554 days
2025-01-31: 118K2025-02-14: 68K2025-02-28: 125K2025-03-14: 115K2025-03-31: 93K2025-04-15: 72K2025-04-30: 100K2025-05-15: 72K2025-05-30: 37K2025-06-13: 34K2025-06-30: 21K2025-07-15: 21K2025-07-31: 746K2025-08-15: 502K2025-08-29: 440K2025-09-15: 405K2025-09-30: 498K2025-10-15: 693K2025-10-31: 697K2025-11-14: 677K2025-11-28: 702K2025-12-15: 901K2025-12-31: 1.4M2026-01-15: 1.6M2026-01-30: 1.9M
the 30 Jan 2026 report24 earlier reportsnormal: 265K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 15 May 2026Institutional holdings change

    saw 29 13F filers open a new position in the quarter ended 31 Mar 2026, 7.2× the same quarter last year.

    Same quarter last year: 4; its normal quarter is 4.

    See the evidence
    This period
    29 (the quarter ended 31 Mar 2026)
    Normal quarter (median of 8 earlier)
    4
    Typical spread (median absolute deviation)
    1.5
    How far from its usual level
    +8.3
    Same quarter last year
    4
    History used
    1,643 days
    2024-03-31: 22024-06-30: 22024-09-30: 42024-12-31: 42025-03-31: 42025-06-30: 32025-09-30: 132025-12-31: 202026-03-31: 29
    the quarter ended 31 Mar 20268 earlier quartersnormal: 4

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  2. 17 Feb 2026several at once

    had 1.6M shares sold short in the 15 Jan 2026 report, 29× the same report last year, while it saw 20 13F filers open a new position in the quarter ended 31 Dec 2025, 5.0× the same quarter last year. Two unrelated kinds of activity within 14 days.

    See the evidence (3 changes)

    Short interest and volume: Short interest spike became public on 28 Jan 2026

    SAB Biotherapeutics had 1.6M shares sold short in the 15 Jan 2026 report, 29× the same report last year.

    This period
    1.6M (the 15 Jan 2026 report)
    Normal report (median of 24 earlier)
    122K
    Typical spread (median absolute deviation)
    101K
    How far from its usual level
    +9.7
    Same report last year
    53K
    History used
    1,539 days
    2025-01-15: 53K2025-01-31: 118K2025-02-14: 68K2025-02-28: 125K2025-03-14: 115K2025-03-31: 93K2025-04-15: 72K2025-04-30: 100K2025-05-15: 72K2025-05-30: 37K2025-06-13: 34K2025-06-30: 21K2025-07-15: 21K2025-07-31: 746K2025-08-15: 502K2025-08-29: 440K2025-09-15: 405K2025-09-30: 498K2025-10-15: 693K2025-10-31: 697K2025-11-14: 677K2025-11-28: 702K2025-12-15: 901K2025-12-31: 1.4M2026-01-15: 1.6M
    the 15 Jan 2026 report24 earlier reportsnormal: 122K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Institutional holdings: Many funds opening a new position became public on 17 Feb 2026

    SAB Biotherapeutics saw 20 13F filers open a new position in the quarter ended 31 Dec 2025, 5.0× the same quarter last year.

    This period
    20 (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    4
    Typical spread (median absolute deviation)
    1.5
    How far from its usual level
    +5.3
    Same quarter last year
    4
    History used
    1,553 days
    2023-12-31: 102024-03-31: 22024-06-30: 22024-09-30: 42024-12-31: 42025-03-31: 42025-06-30: 32025-09-30: 132025-12-31: 20
    the quarter ended 31 Dec 20258 earlier quartersnormal: 4

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Short interest and volume: Short interest spike became public on 11 Feb 2026

    SAB Biotherapeutics had 1.9M shares sold short in the 30 Jan 2026 report, 16× the same report last year.

    This period
    1.9M (the 30 Jan 2026 report)
    Normal report (median of 24 earlier)
    265K
    Typical spread (median absolute deviation)
    232K
    How far from its usual level
    +4.9
    Same report last year
    118K
    History used
    1,554 days
    2025-01-31: 118K2025-02-14: 68K2025-02-28: 125K2025-03-14: 115K2025-03-31: 93K2025-04-15: 72K2025-04-30: 100K2025-05-15: 72K2025-05-30: 37K2025-06-13: 34K2025-06-30: 21K2025-07-15: 21K2025-07-31: 746K2025-08-15: 502K2025-08-29: 440K2025-09-15: 405K2025-09-30: 498K2025-10-15: 693K2025-10-31: 697K2025-11-14: 677K2025-11-28: 702K2025-12-15: 901K2025-12-31: 1.4M2026-01-15: 1.6M2026-01-30: 1.9M
    the 30 Jan 2026 report24 earlier reportsnormal: 265K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  3. 17 Feb 2026Institutional holdings change

    saw 20 13F filers open a new position in the quarter ended 31 Dec 2025, 5.0× the same quarter last year.

    Same quarter last year: 4; its normal quarter is 4.

    See the evidence
    This period
    20 (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    4
    Typical spread (median absolute deviation)
    1.5
    How far from its usual level
    +5.3
    Same quarter last year
    4
    History used
    1,553 days
    2023-12-31: 102024-03-31: 22024-06-30: 22024-09-30: 42024-12-31: 42025-03-31: 42025-06-30: 32025-09-30: 132025-12-31: 20
    the quarter ended 31 Dec 20258 earlier quartersnormal: 4

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  4. 11 Feb 2026Short interest and volume change

    had 1.9M shares sold short in the 30 Jan 2026 report, 16× the same report last year.

    Same report last year: 118K; its normal report is 265K.

    See the evidence
    This period
    1.9M (the 30 Jan 2026 report)
    Normal report (median of 24 earlier)
    265K
    Typical spread (median absolute deviation)
    232K
    How far from its usual level
    +4.9
    Same report last year
    118K
    History used
    1,554 days
    2025-01-31: 118K2025-02-14: 68K2025-02-28: 125K2025-03-14: 115K2025-03-31: 93K2025-04-15: 72K2025-04-30: 100K2025-05-15: 72K2025-05-30: 37K2025-06-13: 34K2025-06-30: 21K2025-07-15: 21K2025-07-31: 746K2025-08-15: 502K2025-08-29: 440K2025-09-15: 405K2025-09-30: 498K2025-10-15: 693K2025-10-31: 697K2025-11-14: 677K2025-11-28: 702K2025-12-15: 901K2025-12-31: 1.4M2026-01-15: 1.6M2026-01-30: 1.9M
    the 30 Jan 2026 report24 earlier reportsnormal: 265K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  5. 28 Jan 2026Short interest and volume change

    had 1.6M shares sold short in the 15 Jan 2026 report, 29× the same report last year.

    Same report last year: 53K; its normal report is 122K.

    See the evidence
    This period
    1.6M (the 15 Jan 2026 report)
    Normal report (median of 24 earlier)
    122K
    Typical spread (median absolute deviation)
    101K
    How far from its usual level
    +9.7
    Same report last year
    53K
    History used
    1,539 days
    2025-01-15: 53K2025-01-31: 118K2025-02-14: 68K2025-02-28: 125K2025-03-14: 115K2025-03-31: 93K2025-04-15: 72K2025-04-30: 100K2025-05-15: 72K2025-05-30: 37K2025-06-13: 34K2025-06-30: 21K2025-07-15: 21K2025-07-31: 746K2025-08-15: 502K2025-08-29: 440K2025-09-15: 405K2025-09-30: 498K2025-10-15: 693K2025-10-31: 697K2025-11-14: 677K2025-11-28: 702K2025-12-15: 901K2025-12-31: 1.4M2026-01-15: 1.6M
    the 15 Jan 2026 report24 earlier reportsnormal: 122K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  6. 13 Jan 2026Short interest and volume change

    had 1.4M shares sold short in the 31 Dec 2025 report, 40× the same report last year.

    Same report last year: 36K; its normal report is 117K.

    See the evidence
    This period
    1.4M (the 31 Dec 2025 report)
    Normal report (median of 24 earlier)
    117K
    Typical spread (median absolute deviation)
    89K
    How far from its usual level
    +10.1
    Same report last year
    36K
    History used
    1,524 days
    2024-12-31: 36K2025-01-15: 53K2025-01-31: 118K2025-02-14: 68K2025-02-28: 125K2025-03-14: 115K2025-03-31: 93K2025-04-15: 72K2025-04-30: 100K2025-05-15: 72K2025-05-30: 37K2025-06-13: 34K2025-06-30: 21K2025-07-15: 21K2025-07-31: 746K2025-08-15: 502K2025-08-29: 440K2025-09-15: 405K2025-09-30: 498K2025-10-15: 693K2025-10-31: 697K2025-11-14: 677K2025-11-28: 702K2025-12-15: 901K2025-12-31: 1.4M
    the 31 Dec 2025 report24 earlier reportsnormal: 117K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  7. 7 Jan 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  8. 7 Jan 2026Filings record

    Director or officer change

  9. 25 Dec 2025Short interest and volume change

    had 901K shares sold short in the 15 Dec 2025 report, 16× the same report last year.

    Same report last year: 56K; its normal report is 107K.

    See the evidence
    This period
    901K (the 15 Dec 2025 report)
    Normal report (median of 24 earlier)
    107K
    Typical spread (median absolute deviation)
    72K
    How far from its usual level
    +7.4
    Same report last year
    56K
    History used
    1,508 days
    2024-12-13: 56K2024-12-31: 36K2025-01-15: 53K2025-01-31: 118K2025-02-14: 68K2025-02-28: 125K2025-03-14: 115K2025-03-31: 93K2025-04-15: 72K2025-04-30: 100K2025-05-15: 72K2025-05-30: 37K2025-06-13: 34K2025-06-30: 21K2025-07-15: 21K2025-07-31: 746K2025-08-15: 502K2025-08-29: 440K2025-09-15: 405K2025-09-30: 498K2025-10-15: 693K2025-10-31: 697K2025-11-14: 677K2025-11-28: 702K2025-12-15: 901K
    the 15 Dec 2025 report24 earlier reportsnormal: 107K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  10. 10 Dec 2025Short interest and volume change

    had 702K shares sold short in the 28 Nov 2025 report, 7.1× the same report last year.

    Same report last year: 99K; its normal report is 99K.

    See the evidence
    This period
    702K (the 28 Nov 2025 report)
    Normal report (median of 24 earlier)
    99K
    Typical spread (median absolute deviation)
    63K
    How far from its usual level
    +6.5
    Same report last year
    99K
    History used
    1,491 days
    2024-11-29: 99K2024-12-13: 56K2024-12-31: 36K2025-01-15: 53K2025-01-31: 118K2025-02-14: 68K2025-02-28: 125K2025-03-14: 115K2025-03-31: 93K2025-04-15: 72K2025-04-30: 100K2025-05-15: 72K2025-05-30: 37K2025-06-13: 34K2025-06-30: 21K2025-07-15: 21K2025-07-31: 746K2025-08-15: 502K2025-08-29: 440K2025-09-15: 405K2025-09-30: 498K2025-10-15: 693K2025-10-31: 697K2025-11-14: 677K2025-11-28: 702K
    the 28 Nov 2025 report24 earlier reportsnormal: 99K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  11. 26 Nov 2025Short interest and volume change

    had 677K shares sold short in the 14 Nov 2025 report, 17× the same report last year.

    Same report last year: 40K; its normal report is 96K.

    See the evidence
    This period
    677K (the 14 Nov 2025 report)
    Normal report (median of 24 earlier)
    96K
    Typical spread (median absolute deviation)
    57K
    How far from its usual level
    +6.8
    Same report last year
    40K
    History used
    1,477 days
    2024-11-15: 40K2024-11-29: 99K2024-12-13: 56K2024-12-31: 36K2025-01-15: 53K2025-01-31: 118K2025-02-14: 68K2025-02-28: 125K2025-03-14: 115K2025-03-31: 93K2025-04-15: 72K2025-04-30: 100K2025-05-15: 72K2025-05-30: 37K2025-06-13: 34K2025-06-30: 21K2025-07-15: 21K2025-07-31: 746K2025-08-15: 502K2025-08-29: 440K2025-09-15: 405K2025-09-30: 498K2025-10-15: 693K2025-10-31: 697K2025-11-14: 677K
    the 14 Nov 2025 report24 earlier reportsnormal: 96K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  12. 13 Nov 2025Short interest and volume change

    had 697K shares sold short in the 31 Oct 2025 report, 12× the same report last year.

    Same report last year: 59K; its normal report is 82K.

    See the evidence
    This period
    697K (the 31 Oct 2025 report)
    Normal report (median of 24 earlier)
    82K
    Typical spread (median absolute deviation)
    43K
    How far from its usual level
    +9.8
    Same report last year
    59K
    History used
    1,463 days
    2024-10-31: 59K2024-11-15: 40K2024-11-29: 99K2024-12-13: 56K2024-12-31: 36K2025-01-15: 53K2025-01-31: 118K2025-02-14: 68K2025-02-28: 125K2025-03-14: 115K2025-03-31: 93K2025-04-15: 72K2025-04-30: 100K2025-05-15: 72K2025-05-30: 37K2025-06-13: 34K2025-06-30: 21K2025-07-15: 21K2025-07-31: 746K2025-08-15: 502K2025-08-29: 440K2025-09-15: 405K2025-09-30: 498K2025-10-15: 693K2025-10-31: 697K
    the 31 Oct 2025 report24 earlier reportsnormal: 82K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  13. 25 Oct 2025Short interest and volume change

    had 693K shares sold short in the 15 Oct 2025 report, 8.7× the same report last year.

    Same report last year: 80K; its normal report is 76K.

    See the evidence
    This period
    693K (the 15 Oct 2025 report)
    Normal report (median of 24 earlier)
    76K
    Typical spread (median absolute deviation)
    39K
    How far from its usual level
    +10.6
    Same report last year
    80K
    History used
    1,447 days
    2024-10-15: 80K2024-10-31: 59K2024-11-15: 40K2024-11-29: 99K2024-12-13: 56K2024-12-31: 36K2025-01-15: 53K2025-01-31: 118K2025-02-14: 68K2025-02-28: 125K2025-03-14: 115K2025-03-31: 93K2025-04-15: 72K2025-04-30: 100K2025-05-15: 72K2025-05-30: 37K2025-06-13: 34K2025-06-30: 21K2025-07-15: 21K2025-07-31: 746K2025-08-15: 502K2025-08-29: 440K2025-09-15: 405K2025-09-30: 498K2025-10-15: 693K
    the 15 Oct 2025 report24 earlier reportsnormal: 76K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  14. 30 Sep 2025Filings record

    Director or officer change

  15. 26 Sep 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  16. 26 Sep 2025Filings record

    Director or officer change

  17. 27 Aug 2025Short interest and volume change

    had 502K shares sold short in the 15 Aug 2025 report, 19× the same report last year.

    Same report last year: 26K; its normal report is 58K.

    See the evidence
    This period
    502K (the 15 Aug 2025 report)
    Normal report (median of 24 earlier)
    58K
    Typical spread (median absolute deviation)
    23K
    How far from its usual level
    +8.9
    Same report last year
    26K
    History used
    1,386 days
    2024-08-15: 26K2024-08-30: 35K2024-09-13: 30K2024-09-30: 41K2024-10-15: 80K2024-10-31: 59K2024-11-15: 40K2024-11-29: 99K2024-12-13: 56K2024-12-31: 36K2025-01-15: 53K2025-01-31: 118K2025-02-14: 68K2025-02-28: 125K2025-03-14: 115K2025-03-31: 93K2025-04-15: 72K2025-04-30: 100K2025-05-15: 72K2025-05-30: 37K2025-06-13: 34K2025-06-30: 21K2025-07-15: 21K2025-07-31: 746K2025-08-15: 502K
    the 15 Aug 2025 report24 earlier reportsnormal: 58K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  18. 12 Aug 2025Short interest and volume change

    had 746K shares sold short in the 31 Jul 2025 report, 26× the same report last year.

    Same report last year: 29K; its normal report is 55K.

    See the evidence
    This period
    746K (the 31 Jul 2025 report)
    Normal report (median of 24 earlier)
    55K
    Typical spread (median absolute deviation)
    23K
    How far from its usual level
    +13.8
    Same report last year
    29K
    History used
    1,371 days
    2024-07-31: 29K2024-08-15: 26K2024-08-30: 35K2024-09-13: 30K2024-09-30: 41K2024-10-15: 80K2024-10-31: 59K2024-11-15: 40K2024-11-29: 99K2024-12-13: 56K2024-12-31: 36K2025-01-15: 53K2025-01-31: 118K2025-02-14: 68K2025-02-28: 125K2025-03-14: 115K2025-03-31: 93K2025-04-15: 72K2025-04-30: 100K2025-05-15: 72K2025-05-30: 37K2025-06-13: 34K2025-06-30: 21K2025-07-15: 21K2025-07-31: 746K
    the 31 Jul 2025 report24 earlier reportsnormal: 55K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  19. 5 Aug 2025Filings record

    Private placement of securities (Form D)

  20. 5 Feb 2025Filings record

    Completed an acquisition or asset sale

  21. 31 Jul 2024Filings record

    Director or officer change

  22. 30 May 2024Filings record

    Director or officer change

  23. 15 May 2024Filings record

    Report will be filed late

  24. 7 May 2024Filings record

    Director or officer change

  25. 8 Mar 2024Filings record

    Director or officer change

  26. 2 Feb 2024Filings record

    Director or officer change

  27. 9 Dec 2023Insiders record

    Sullivan Eddie Joe (Chief Executive Officer) bought 1,740 shares of SABS ($1,531) (dated 8 Dec 2023)

  28. 1 Dec 2023Insiders record

    King Michael (CHIEF FINANCIAL OFFICER) bought 5,000 shares of SABS ($4,500) (dated 30 Nov 2023)

  29. 1 Dec 2023Insiders record

    Reich Samuel J (Executive Chairman) bought 11,000 shares of SABS ($9,790) (dated 30 Nov 2023)

  30. 20 Nov 2023Filings record

    Director or officer change

  31. 27 Oct 2023Filings record

    Director or officer change

  32. 16 Oct 2023Filings record

    Private placement of securities (Form D)

  33. 2 Oct 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  34. 2 Oct 2023Filings record

    Director or officer change

  35. 21 Aug 2023Filings record

    Changed its auditor

  36. 14 Aug 2023Filings record

    Report will be filed late

  37. 31 Jul 2023Filings record

    Changed its auditor

  38. 25 May 2023Short interest and volume change

    had 665K shares sold short in the 15 May 2023 report, 2.6× the same report last year.

    Same report last year: 259K; its normal report is 231K.

    See the evidence
    This period
    665K (the 15 May 2023 report)
    Normal report (median of 24 earlier)
    231K
    Typical spread (median absolute deviation)
    33K
    How far from its usual level
    +8.7
    Same report last year
    259K
    History used
    563 days
    2022-05-13: 259K2022-05-31: 310K2022-06-15: 248K2022-06-30: 291K2022-07-15: 265K2022-07-29: 256K2022-08-15: 240K2022-08-31: 255K2022-09-15: 198K2022-09-30: 244K2022-10-14: 262K2022-10-31: 222K2022-11-15: 240K2022-11-30: 214K2022-12-15: 201K2022-12-30: 172K2023-01-13: 147K2023-01-31: 152K2023-02-15: 147K2023-02-28: 168K2023-03-15: 198K2023-03-31: 138K2023-04-14: 134K2023-04-28: 519K2023-05-15: 665K
    the 15 May 2023 report24 earlier reportsnormal: 231K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  39. 10 May 2023Short interest and volume change

    had 519K shares sold short in the 28 Apr 2023 report, 2.0× the same report last year.

    Same report last year: 265K; its normal report is 231K.

    See the evidence
    This period
    519K (the 28 Apr 2023 report)
    Normal report (median of 24 earlier)
    231K
    Typical spread (median absolute deviation)
    33K
    How far from its usual level
    +5.8
    Same report last year
    265K
    History used
    546 days
    2022-04-29: 265K2022-05-13: 259K2022-05-31: 310K2022-06-15: 248K2022-06-30: 291K2022-07-15: 265K2022-07-29: 256K2022-08-15: 240K2022-08-31: 255K2022-09-15: 198K2022-09-30: 244K2022-10-14: 262K2022-10-31: 222K2022-11-15: 240K2022-11-30: 214K2022-12-15: 201K2022-12-30: 172K2023-01-13: 147K2023-01-31: 152K2023-02-15: 147K2023-02-28: 168K2023-03-15: 198K2023-03-31: 138K2023-04-14: 134K2023-04-28: 519K
    the 28 Apr 2023 report24 earlier reportsnormal: 231K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  40. 4 Apr 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

Showing the newest 40 of 79 entries; narrow the window or the kind of data to see older ones.

Not listed: 67 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001833214
Ticker
SABS
Domain
sab.bio
Hq location
FL|MIAMI BEACH|33140 (1 unverified)
Lobbying client
sab biotherapeutics
Name
Aurochs LLC, a South Dakota LLC, Big Cypress Acquisition Corp., Diversity Therapeutics, Inc., a Delaware Corporation, EX-21.1 and 6 more
  • Federal lobbying disclosures (LDA)6 records, 51 data points30 Sep 2014 to 31 Dec 2022
  • SEC Form 13F institutional holdings189 data points30 Sep 2021 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)104 records7 Dec 2020 to 5 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)340 data points31 Dec 2019 to 2 Nov 2026
  • SEC Form 4 insider transactions13 records, 32 data points14 Jan 2021 to 8 Dec 2023
  • FINRA short interest (twice monthly)360 data points29 Oct 2021 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)2550 data points25 Oct 2021 to 20 Nov 2026